Principal Financial Group Inc. Purchases Shares of 52,264 Theravance Biopharma, Inc. $TBPH

Principal Financial Group Inc. acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,264 shares of the biopharmaceutical company’s stock, valued at approximately $848,000.

A number of other institutional investors also recently made changes to their positions in TBPH. Vanguard Group Inc. grew its position in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp lifted its holdings in Theravance Biopharma by 4.4% during the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after purchasing an additional 45,987 shares during the last quarter. Geode Capital Management LLC boosted its stake in Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after purchasing an additional 40,734 shares during the period. Dimensional Fund Advisors LP boosted its stake in Theravance Biopharma by 12.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after purchasing an additional 92,253 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma in the 3rd quarter valued at $10,611,000. Institutional investors own 99.10% of the company’s stock.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the completion of the transaction, the insider directly owned 9,174,453 shares in the company, valued at $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 350,011 shares of company stock worth $6,008,309 in the last quarter. 7.65% of the stock is currently owned by company insiders.

Theravance Biopharma Stock Up 0.1%

Shares of Theravance Biopharma stock opened at $16.86 on Friday. Theravance Biopharma, Inc. has a 12-month low of $10.82 and a 12-month high of $21.03. The company has a market capitalization of $869.13 million, a price-to-earnings ratio of 7.66 and a beta of 0.17. The firm’s 50-day moving average price is $16.71 and its two-hundred day moving average price is $17.05.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, sell-side analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on TBPH. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, B. Riley Financial boosted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.